ALK and lung carcinoma: It has also been reported in the literature that the mutation status of EGFR/KRAS/ALK/TP53 genes is associated with metastasis in different tissues and organs of lung cancer; in lung adenocarcinoma (LADC) patients, KRAS mutation frequency showed changes related to the metastatic site, and KRAS mutation was associated with significant poor prognosis in cases of bone metastasis.27